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Abstract
Summary The WHO fracture risk assessment (FRAX) and
Canadian Association of Radiologists and Osteoporosis Can-
ada (CAROC) tools can both be used to determine an individ-
ual’s 10-year risk of osteoporotic fracture. However, these
tools differ in their risk calculation. For participants <65 years
with a wrist fracture, FRAX provides a lower fracture risk
estimate than CAROC resulting in fewer decisions to initiate
therapy.
Methods Individuals ≥50 years with a distal radius fracture
resulting from a fall from standing height or less were recruit-
ed from a single orthopedic clinic. Participants underwent a
DXA scan of their lumbar spine and hip. Femoral neck (FN)
bone mineral density (BMD) and fracture risk factors were
used to determine each participant’s 10-year fracture risk
using both fracture risk assessment tools. Participants were
categorized as low (<10 %), moderate (10–20 %), or high
(>20 %) risk. Stratified by age (<65 years, >65 years), the
proportion of participants in each category was compared be-
tween the tools.
Results Analyses included 60 participants (mean age 65.7±
9.6 years). In those <65 years (n=26), the proportion of indi-
viduals at low, moderate, and high risk differed between the
FRAX and CAROC tools (p<0.0001). FRAX categorized
69 % as low (CAROC 0 %) and 3 % as high (CAROC
12 %) risk. For individuals >65 years, almost all were at least
at moderate risk (FRAX 79%, CAROC 53%), but fewer were
at high risk using FRAX (18 vs. 47 %, p<0.0003).
Conclusion For participants <65 years with a wrist fracture,
FRAX provides a lower estimate of 10-year fracture risk than
CAROC resulting in fewer decisions to initiate therapy. How-
ever, almost all participants >65 years were at moderate or
high risk under both FRAX and CAROC and should at least
be considered for pharmacotherapy.
Keywords Osteoporosis . Distal radius fracture . Clinical
practice guidelines . Fracture risk . FRAX
Introduction
Following publication of the 2010 clinical practice guidelines
(CPG) for the diagnosis and management of osteoporosis in
Canada [1], Osteoporosis Canada emphasized the need to
evaluate future fracture risk in all older individuals who expe-
rience a major Bfragility^ fracture typically associated with
osteoporosis (i.e., hip, clinical or morphometric vertebra, pel-
vis, and forearm or proximal humerus).
In Canada, two fracture risk prediction tools exist to deter-
mine an individual’s 10-year risk of osteoporotic fracture. The
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Purpose The purpose of the current report is to compare frac-
ture risk prediction rates using the CAROC and the FRAX®
tools.
Canada (CAROC) tool stratifies women and men >50 years
into three categories of osteoporotic fracture risk: low
(<10%), moderate (10–20%), and high (>20%) [2]. Baseline
risk is assessed using age, sex, and femoral neck T-score. The
presence of a prior fragility fracture after age 40 [3] or recent
prolonged use of systemic glucocorticoids increases fracture
risk into the next highest category independent of bone min-
eral density (BMD). The World Health Organization Fracture
Risk Assessment (FRAX©) tool uses additional risk factors
over and above those used in CAROC (e.g., parental history
of hip fracture) [4]. Lumbar spine BMD is not considered in
either tool.
Overall, observed fracture rates for Canadians are in close
agreement to the rates predicted by both tools [5]. Osteoporosis
Canada recommended the CAROC tool be adopted in prefer-
ence to FRAX based on its relative simplicity and wider na-
tional availability. The CPG recommend that all high-risk indi-
viduals be offered pharmacotherapy, while those at moderate
risk be regarded with some circumspection before initiating
therapy and only considered if there are other risk factors and
in accordance with patient preference. This is important in pri-
mary practice considering wrist fractures comprise 26–46 % of
all observed skeletal fractures [6–11] and are the most common
fragility fracture seen in fracture clinics in this age group.
Although a fragility fracture increases the risk for future
fractures, there is evidence that wrist fractures are associated
with significantly lower re-fracture rates in the following 5–
10 years than is observed following other Bosteoporotic^ frac-
tures (e.g., vertebra, hip, or proximal humerus), especially in
younger individuals with non-osteoporotic BMD values [12].
Here, we compare the results of applying the CAROC and
FRAX tools to 60 participants presenting to a single orthope-
dic clinic after a wrist fracture to assess differences in treat-
ment directives resulting from their respective risk
stratification.
Methods
Individuals ≥50 years old presenting with a fragility fracture
[13] of the distal forearm were recruited from the orthopedic
clinic at St. Joseph’s Health Care, London, Ontario. Individuals
previously diagnosed with osteoporosis by self-report or cur-
rently taking osteoporosis medication were excluded. Given
that the study’s primary goal was to observe the response of
family physicians to the patients’ fracture risk reported by
CAROC or FRAX (prescribed treatment or not), participants
who had not previously been diagnosed with osteoporosis or
who had not been treated for osteoporosis were the target study
population [14]. Subjects consented to enrolment in a clinical
study designed to monitor treatment outcomes from their fam-
ily physicians and were provided with BMD assessments. A
trained research assistant collected baseline demographic
information and information about fragility fractures after age
40 years. BMD testing was performed on a Lunar Prodigy
Advance system (GE Healthcare, with a precision of ±0.01 g/
cm2 at the femoral neck). Under current guidelines, only the
femoral neck T-score was used for risk categorization.
Osteophytic artifact due to degenerative disk disease, facet joint
arthropathy, etc. formed part of the lumbar spine report struc-
ture if visually apparent on the densitometer images. All BMD
reports were read by one trained clinician (ABH).
The purpose of the current report is to compare and contrast
the risk categorization between the CAROC and FRAX tools
when applied to all 60 participants. The Canadian reference
population was used for the FRAX calculation. Each partici-
pant’s fracture risk was assessed using each tool. Incomplete
information on parental history of hip fracture collected at study
entry might have systematically underestimated future fracture
risk calculated for FRAX. We address the question of whether
the use of either tool in primary practice will lead to the same or
discordant therapeutic decisions. This study was approved by
the Institutional Review Board for Research involving Human
Subjects at Western University and the Hamilton Integrated
Research Ethics Board at McMaster University.
Analyses
Baseline demographic data are reported as means (SD). Sta-
tistical differences between younger and older participants
were defined by Student’s t test. Categorical differences in
the proportion of participants assigned to the three risk cat-
egories between the CAROC and FRAX systems were eval-
uated by testing for marginal homogeneity using the
Bhapkar test.
Results
Baseline demographic data are shown for all participants strat-
ified by age (Table 1). For all 60 participants, the mean age
was 65.7±9.6 years. Almost half (n=26 [43%]) were younger
than 65 years, <20 % were men and 18 (30 %) recalled a
parental history of either osteoporosis or fracture. Few were
currently taking glucocorticoids or undergoing treatment for
rheumatoid arthritis.
Femoral neck T-scores were not lower than expected for
the age- and sex-matched reference population (Table 1).
Femoral neck BMD was significantly (p<0.001) higher in
participants <65 years compared with those >65 years (T-
score −1.1±0.9 vs. −1.5±0.6). Lumbar spine BMD was sim-
ilar between groups, and T-scores were slightly higher than
those at the femoral neck. This is likely explained by a high
prevalence of measurement artifact due to osteophytic disease
(nearly 80 % of cohort).
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In applying the FRAX tool to all participants, the mean 10-
year probability of futuremajor osteoporotic fracture was 12.5
±5.1 %. Fracture probability was significantly lower in those
<65 years than in those >65 years (9.1±4.0 vs. 15.2±4.3 %,
p<0.001) (Table 1).
Table 2 demonstrates the respective differences in risk cat-
egory by the CAROC and FRAX systems based upon the
proportion of participants at low, moderate, and high risk.
Using FRAX, 19 (32 %) of all participants were at low risk
while only 7 (12 %) were at high risk. Differences in the
proportions of participants categorized according to their frac-
ture risk were significant (p≤0.001) whether analyzed for all
ages combined, in younger or older participants.
In the 26 participants <65 years, FRAX categorized 18
(69 %) as low risk and only 1 (3 %) as high risk. None of
the participants <65 years was low risk by CAROC due to an
automatic increase of one risk category based upon the pres-
ence of a prior fragility wrist fracture. CAROC categorized 23
(88 %) as moderate and 3 (12 %) as high risk.
For participants >65 years, almost all were at least at mod-
erate risk (FRAX 79 %, CAROC 53 %), but FRAX catego-
rized fewer participants as high risk (18 vs. 47 %).
Discussion
It is clear that the two fracture risk assessment tools available
to Canadian physicians provide significantly different risk es-
timates for adults presenting with a wrist fracture, particularly
in those <65 years. In the current study, more than half of wrist
fractures occurred in individuals <65 years of age in whom
average femoral neck T-scores were considerably higher than
−2.5 and typically average for age. For this important group of
individuals, the operating characteristics of FRAX differ sig-
nificantly from CAROC. The FRAX algorithm provides a
continuous assessment of future fracture risk and includes
prevalent fragility fractures within the statistical modeling.
Table 1 Baseline characteristics
for all participants and stratified
by age
All <65 years >65 years p valuea
Number of subjects 60 26 34
Age, years 65.7±9.6 56.7±4.6 72.5±6.0 <0.001
Female/male 49/11 21/5 28/6
Fracture prior to current wrist fracture 2 2 0
Family history of osteoporosis 18 9 9
Current steroid therapy 2 0 2
Rheumatoid arthritis 3 1 2
FRAX patients
Femoral neck BMD, g/cm2 0.85±0.12 0.91±0.16 0.81±0.06 0.022
Femoral neck T-score −1.2±0.9 −0.8±1.2 −1.5±0.6 0.034
Lumbar spine BMD, L2–L4, g/cm
2 1.15±0.24 1.12±0.24 1.17±0.25 NS
Lumbar spine T-score −0.5±2.0 −0.7±1.9 −0.3±2.0 NS
CAROC patients
Femoral neck BMD, g/cm2 0.87±0.10 0.92±0.11 0.82±0.06 0.003
Femoral neck T-score −1.0±0.9 −0.5±0.9 −1.4±0.7 0.004
Lumbar spine BMD, L2–L4, g/cm
2 1.13±0.15 1.18±0.18 1.08±0.11 NS
Lumbar spine T-score −0.6±1.3 −0.2±1.5 −0.98±1.0 NS
FRAX, 10-year probability of future fragility fracture, % 12.5±5.1 9.1±4.0 15.2±4.3 <0.001
NS not significant
a p values represent comparisons between <65 years and >65 years
Table 2 Fracture risk category for all participants and those younger
and older than 65 years using FRAX and CAROC
FRAX CAROC
All subjects, n=60a N (%) N (%)
Low 19 (32) 0
Moderate 34 (57) 41 (68)
High 7 (12) 19 (32)
Age <65 years, n=26a
Low 18 (69) 0
Moderate 7 (27) 23 (88)
High 1 (4) 3 (12)
Age>65 years, n=34a
Low 1 (3) 0
Moderate 27 (79) 18 (53)
High 6 (18) 16 (47)
The proportion of subjects assigned to each of the three risk categories is
significantly different between the FRAX and CAROC tools, both for all
subjects, for those ≤65 years and for those >65 years (p<0.001)
a p<0.001 for difference in risk categorization
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Using FRAX, participants with prior fractures may still be at
low risk of future fractures. On the other hand, CAROC
does not predict a low risk in anyone presenting with a
fragility fracture. Even if the measured BMD indicates ex-
cellent bone mass, the baseline low risk will be increased to
moderate risk by the prevalent fracture. Thus, FRAX cate-
gorized two thirds of those <65 years as low risk—a group
for whom the 2010 CPG advise no consideration for phar-
macological intervention. Only 1 patient was high risk and
thus a candidate for initiating therapy. The picture is very
different when CAROC is used. All participants <65 years
would at least be considered for pharmacotherapy, as they
were at moderate (88 %) or high (12 %) risk.
The situation is less disparate in older individuals. In
those >65 years, two and a half times as many were catego-
rized as high risk by the CAROC tool, compared with
FRAX, and would therefore be advised to initiate pharma-
cotherapy. However, all participants otherwise characterized
as moderate risk by CAROC would also be similarly char-
acterized by FRAX; again, these individuals should at least
be considered for pharmacotherapy, depending on other risk
factors and patient preferences.
It is now generally accepted that any prevalent fragility frac-
ture is a marker of increased fracture risk. This was first clearly
demonstrated for clinical and/or morphometric vertebral frac-
tures [15, 16], but has been confirmed for all fragility fractures
in epidemiological cohort studies and in large randomized con-
trolled trials of new osteoporosis therapies in which individuals
specifically at risk for fragility fractures were studied [3]. The
risk of subsequent fracture after wrist fracture may, in part, be
age- and gender-dependent, as demonstrated by [17] et al., with
women <70 years of age having been shown to have no in-
crease in subsequent hip fracture risk.
Hodsman et al. evaluated the risk of refracture in women
presenting with a primary wrist fracture. In this study, the
observed 10-year refracture rate across all ages (≥50 years)
was 14.2 % (95 % CI, 11.9–16.5), consistently in the moder-
ate risk category. This rate was significantly lower for indi-
viduals <65 years (compared to those >65 years) and for
individuals with T-scores >−2.5 [12]. Thus, some individuals
are clearly at low risk of refracturing after a primary wrist
fracture and would not be advised to initiate treatment under
the current CPG. This is important considering wrist fractures
comprise up to 50 % of the clinical fragility fracture burden
within the population.
Many individuals view their wrist fracture as an unfortu-
nate result of a traumatic fall and are reluctant to have their
accident Bmedicalised^ to the point of starting an osteoporotic
treatment. The FRAX tool allows the practitioner a more flex-
ible environment in which to arrive at an informed decision
with the patient around the initiation of therapy. FRAX may
be the preferred tool as it will be more conservative in
selecting individuals for pharmacotherapy.
This argument may be especially relevant for individuals
<65 years presenting with a wrist fracture. Provided the wrist
fracture is the first Bfragility^ fracture in adult life, and after
confirming there is no evidence for morphometric vertebral
compression fractures, the physician may consider such indi-
viduals at low risk for refracture. Regardless, planned surveil-
lance with interval BMDmonitoring should be the standard of
care for all individuals with a wrist fracture in whom a con-
servative approach is adopted.
Limitations
Results from this small study clearly demonstrate that the
FRAX and CAROC fracture risk prediction tools provide dif-
ferent estimates of the likelihood of future Bosteoporotic^ frac-
tures following a wrist fracture, particularly in individuals
<65 years. However, this requires validation by applying each
tool prospectively to BMD measurements obtained from
population-based studies in which future fractures are docu-
mented in those presenting with primary wrist fractures.
Conclusions
For individuals <65 years who have sustained a wrist fracture,
the FRAX tool provides a lower 10-year fracture risk estimate
than CAROC and appropriately results in fewer decisions to
initiate therapy. However, almost all individuals >65 years are
at moderate or high risk under both FRAX and CAROC and
should at least be considered for pharmacotherapy.
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